Strides Pharma Science Ltd Q1 FY27 Earnings Analysis

- U.S. business growth expected to accelerate from H2 FY27 onwards with new product launches, including nasal sprays and controlled substances. - Targeted U.S. revenue aspiration of $375 million to $400 million by FY28, representing about 15%-20% CAGR from current base. - Controlled substances business is a new growth engine; additional quota allocations pending with DEA may drive future growth. - Nasal sprays and complex generics (transdermals, films) expected to contribute meaningfully from FY28 and FY29 onwards. - Ex-U.S. markets showing strong, consistent growth with 21% CAGR in FY26 and growing faster than the U.S. market. - Product launches and portfolio rationalization strategies focus on profitability and sustainable revenue growth. - Growth drivers include expanded global R&D, strategic partnerships, and deeper penetration in key regulated and emerging markets.

- Strides expects sequential quarter-on-quarter growth, continuing the trend seen in FY26 Q4 with 11% growth (14% excluding institutional business). - For FY28, the U.S. revenue guidance is $375 million to $400 million, targeting a 15% to 20% CAGR from the current base. - Operational PAT grew 20% YoY in Q4 FY26 with a margin of 10.3%; full-year operational PAT grew 50% YoY, crossing INR 518 crores. - EBITDA margins targeted between 18% to 20%, with a long-term goal above 20%. - EPS has improved significantly, with operational EPS for FY26 at INR 56.2 and Q4 at INR 14.7, reflecting strong earnings quality; the company aims to sustain and grow EPS. - Growth engines include controlled substances and complex generics (nasal sprays, transdermals), expected to contribute meaningfully FY28 onwards. - Focus remains on profitability, operational leverage, and margin maintenance despite cost pressures.

- Total capital investments in FY26 were INR418 crores, including: - INR236 crores tangible capex focused on: - Nasal spray capabilities development - Enhancing capacities for Ex-U.S. business - Acquisition of new office space in the U.K. - INR182 crores intangible investments covering: - Acquisition of global product rights to drive growth in U.S. and Ex-U.S. markets - Significant upgrade to global ERP platform migrating to SAP HANA - Future capex run rate expected around INR300 crores annually over next 2 years: - Tangible capex largely maintenance capex after recent growth investments - Intangible investments expected to continue for acquiring global rights and fast-tracking growth - Investments in complex generics like nasal sprays, transdermals, and films targeting meaningful revenue from FY28 onwards - Acquisition of certain Sandoz products in Feb '26 to strengthen presence in Africa starting H2 FY27

- There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript. - The company has focused on disciplined capital allocation and has strengthened its balance sheet over recent years. - Net debt-to-EBITDA ratio improved from 1.9x to 1.55x as of FY26, showing effective debt reduction and deleveraging. - Despite increased investments in growth capital (INR418 crores in FY26), the company has managed cash flows well without indicating a need for fresh fundraising. - The company’s management discusses confidence in improving net debt metrics over the coming quarters, implying continued self-funded growth rather than reliance on additional fundraising. - Any major acquisition or intangible investments seem to be funded through existing resources or operational cash flows.

The transcript from the Strides Pharma Science Limited Q4 FY26 Earnings Call does not explicitly mention details about the current or expected order book or pending orders. However, relevant points related to business outlook and growth include: - The company is focusing on increasing controlled substances quota and expects growth upon receiving additional quota. - New product launches, including nasal sprays and other complex generics, are expected to contribute meaningfully from FY28 onward. - Strong growth in Ex-U.S. markets with consistent sequential improvement. - Ongoing investments in R&D and acquisitions of global rights aimed at fast-tracking growth. - The company maintains enough manufacturing capacity for the next 1-2 years with no immediate major capacity expansion needed. No specific quantification or metrics of order books or pending orders are disclosed in the provided transcript.